Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989564
Funder
Australian Research Council
Funding Amount
$150,000.00
Summary
State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organi ....State-of-the-art facility for human and animal virus research in the Canberra and surrounding regions. New viral diseases continue to emerge and old viruses re-emerge to pose a threat to human and animal health. To combat these, we propose a dedicated viral disease research facility. The centre will include experienced researchers, biotechnology companies and government agencies working on discovery, prevention and treatment of viral diseases. Forging strong scientific links between these organisations will considerably enhance the productivity of these researchers, increase their collaborative and scientific outputs and allow for training of students in the latest technologies. The facility will provide researchers with cutting-edge instrumentation for nationally and internationally important projects that would benefit human health.Read moreRead less
Molecular and antibody analysis of cytomegalovirus (CMV) infection of fetal and placental cells. CMV is a beta herpesvirus with many unknown molecular mechanisms associated with cellular infection. The virus infects placental cells in vivo, although pathogenesis of viral damage to these cells has been extremely difficult to study in vitro. We have commenced a study to i) demonstrate the molecular accompaniments of infection of placental cells in vitro, ii) determine the genotypic characteristics ....Molecular and antibody analysis of cytomegalovirus (CMV) infection of fetal and placental cells. CMV is a beta herpesvirus with many unknown molecular mechanisms associated with cellular infection. The virus infects placental cells in vivo, although pathogenesis of viral damage to these cells has been extremely difficult to study in vitro. We have commenced a study to i) demonstrate the molecular accompaniments of infection of placental cells in vitro, ii) determine the genotypic characteristics of congenital CMV infections, in collaboration with Abbott Diagnostics, and iii) produce an in vivo model of CMV infection to demonstrate the pathogenesis of cellular injury. The combination of molecular expertise at UNSW with monoclonal antibody expertise from Abbott Diagnostics mean this project is unique worldwide.Read moreRead less
Development of SELEX technology (Systematic Evolution of Ligands by EXponential enrichment). A recently developed in vitro genetic selection technique has allowed the isolation of oligonucleotides that can bind target molecules with high affinity and specificity. The strategy know as SELEX (Systematic Evolution of Ligands by EXponential enrichment) uses protein biochemistry and PCR technology, with subsequent repeated rounds of selection and amplification, to screen vast libraries of oligonucle ....Development of SELEX technology (Systematic Evolution of Ligands by EXponential enrichment). A recently developed in vitro genetic selection technique has allowed the isolation of oligonucleotides that can bind target molecules with high affinity and specificity. The strategy know as SELEX (Systematic Evolution of Ligands by EXponential enrichment) uses protein biochemistry and PCR technology, with subsequent repeated rounds of selection and amplification, to screen vast libraries of oligonucleotides (RNA or DNA) for their ability to bind target proteins. This procedure will be developed by UNSW in collaboration with the biotech company BTF Plc., Ltd., to be used in two applications. The first is the research interest of UNSW and involves the development of aptamers against hepatitis C virus. The second lies within the interests of BTF and will involve the development of aptamers against the water borne pathogen Cryptosporidium parvum.Read moreRead less